Diabetes, obesity, fatty liver disease, and atherosclerosis are among the most common, costly, and preventable of all health problems, and mainly due to dysregulation of lipid, glucose or energy metabolism. Metabolic dysregulation may cause a number of other chronic diseases and conditions. The researchers also aim to build a collaborative internationally-recognized Center of Excellence for fundamental and translational research in diabetes, obesity and metabolism.
More than 30 million people in the U.S. have diabetes.
By 2030, non-alcoholic steatohepatitis will be the No. 1 reason for liver transplants in the U.S.
Obesity prevalence in the United States in 2017-18, according to the CDC.
- Uncovered novel pathogenic mechanisms of NAFLD and atherosclerosis
- Identified novel targets for treatment of NAFLD, atherosclerosis, and obesity
- Identified novel mechanisms of bile acid regulation
- Discovered novel roles that non-lipid factors play in vessel blockage
- Dr. Chiang is a recipient of a prestigious Merit Award from NIDDK
- A heart failure study by NEOMED scientists in collaboration with Temple University researchers was recently highlighted in the Journal of Cardiac Failure. Takhar Kasumov, Ph.D., an associate professor of pharmaceutical [...]Read the Story
A disease with a not-so-familiar name that often leads to deadly consequences: That’s one way to describe nonalcoholic fatty liver disease (NAFLD). Nearly 10,000 people convened in Boston for this […]